^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

CC-90002

i
Other names: CC-90002, CC 90002, INBRX-103, Ca ImmRx
Associations
Company:
BMS, Inhibrx Biosci
Drug class:
CD47 inhibitor
Associations
8ms
Effects of a humanized CD47 antibody and recombinant SIRPα proteins on triple negative breast carcinoma stem cells. (PubMed, Front Cell Dev Biol)
This indicates that SIRPα-Fc has CD47-mediated agonist activities in breast cancer stem cells affecting proliferation and metastasis pathways that differ from those of CC-90002. This SIRPα-induced CD47 signaling in breast carcinoma cells may limit the efficacy of SIRPα decoy therapeutics intended to stimulate innate antitumor immune responses.
Journal
|
CD47 (CD47 Molecule) • ALDH1A1 (Aldehyde Dehydrogenase 1 Family Member A1) • SIRPA (Signal Regulatory Protein Alpha)
|
CD47 expression
|
CC-90002
almost3years
Phase 1 study of anti-CD47 monoclonal antibody CC-90002 in patients with relapsed/refractory acute myeloid leukemia and high-risk myelodysplastic syndromes. (PubMed, Ann Hematol)
Despite no unexpected safety findings, the CC-90002-AML-001 study was discontinued in dose escalation for lack of monotherapy activity and evidence of ADAs. However, as other anti-CD47 agents in clinical trials are showing promising early results for AML and MDS, understanding preclinical and clinical differences between individual agents in this class will be of high importance.
Clinical • P1 data • Clinical Trial,Phase I • Journal
|
SIRPA (Signal Regulatory Protein Alpha)
|
CC-90002
over3years
Trial completion
|
CD20 (Membrane Spanning 4-Domains A1)
|
CD20 positive
|
Rituxan (rituximab) • CC-90002
over3years
Modulation of CD47-SIRPα innate immune checkpoint axis with Fc-function detuned anti-CD47 therapeutic antibody. (PubMed, Cancer Immunol Immunother)
Studies in a panel of hematological cancer cell lines showed concentration-dependent CC-90002-mediated phagocytosis in acute lymphoblastic leukemia, acute myeloid leukemia (AML), lenalidomide-resistant multiple myeloma (MM) cell lines and AML cells from patients...Furthermore, the role of macrophages in the CC-90002-mediated antitumor activity was demonstrated by transient depletion of macrophages with liposome-clodronate treatment. In non-human primates, CC-90002 displayed acceptable pharmacokinetic properties and a favorable toxicity profile. These data demonstrate the potential activity of CC-90002 across hematological malignancies and provided basis for clinical studies CC-90002-ST-001 (NCT02367196) and CC-90002-AML-001 (NCT02641002).
Journal
|
CD47 (CD47 Molecule)
|
CD47 overexpression
|
lenalidomide • clodronate disodium • CC-90002 • fenretinide nanoparticle (ST-001 nanoFenretinide)